Showing 81 - 100 results of 25,187 for search '(((( 50 a decrease ) OR ( 50 ((nn decrease) OR (we decrease)) ))) OR ( 5 non decrease ))', query time: 0.72s Refine Results
  1. 81

    Data_Sheet_2_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... by Zhaoshun Jiang (7478243)

    Published 2023
    “…</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …”
  2. 82
  3. 83

    S1 Dataset - by Nelmo Jordão Manjate (16324619)

    Published 2023
    “…This study aimed to estimate the cost of SARS-CoV-2 diagnosis of symptomatic suspected patients by reverse transcription polymerase chain reaction (RT-PCR) and antigen rapid diagnostic tests (Ag-RDT) in Mozambique. We conducted a retrospective cost analysis from the provider’s perspective using a bottom-up, micro-costing approach, and compared the direct costs of two nasopharyngeal Ag-RDTs (Panbio and Standard Q) against the costs of three nasal Ag-RDTs (Panbio, COVIOS and LumiraDx), and RT-PCR. …”
  4. 84

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  5. 85

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  6. 86

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  7. 87

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    “…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”
  8. 88
  9. 89
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95

    Table_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.docx by Yun Ji (464484)

    Published 2022
    “…Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
  16. 96

    Trial profile. by Chanel Avenant (409756)

    Published 2024
    “…<div><p>HIV acquisition risk with norethisterone (NET) enanthate (NET-EN) is reportedly less than for depo-medroxyprogesterone acetate intramuscular (DMPA-IM). We investigated the effects of these progestin-only injectable contraceptives on serum testosterone and sex hormone binding globulin (SHBG) levels, since these may play a role in sexual behavior and HIV acquisition. …”
  17. 97

    DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf by Yun Ji (464484)

    Published 2022
    “…Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
  18. 98
  19. 99
  20. 100